SpectrumX Adds Financial Controller to Management Team
SpectrumX’s Hand Sanitiser Approved for NHS Supply Chain’s NHS Supplier List
Healthcare and pharmaceutical firm SpectrumX has announced that it is prepared to proceed with the clinical development of SPX-001, its respiratory drug candidate.
LONDON--(BUSINESS WIRE)--SpectrumX, a UK-based healthcare and pharmaceutical company, today announces that following a constructive scientific advice meeting with the Medicines and Healthcare products Regulatory Agency (MHRA) on Monday, 14th November, the Company is prepared to move forward with the next stage in clinical development of its respiratory drug candidate SPX-001.
SpectrumX Announces Appointment of New Regional Account Manager, UK South West
LONDON--(BUSINESS WIRE)--SpectrumX, a UK-based healthcare and pharmaceutical company, today announces the launch of Spectricept HLD Body MIST, a skin-safe sporicidal disinfectant body wash targeting pathogens, including Clostridioides difficile (C. difficile) spores which can lead to an antimicrobial-resistant bacterium causing diarrhoea and other serious health-related issues and can be the cause of persistent waves of infection in healthcare facilities. The Company intends to roll out the body wash in hospitals, care homes, and other healthcare facilities to control the quantity of C. difficile spores on surfaces and skin.
LONDON--(BUSINESS WIRE)--SpectrumX, a UK-based healthcare and pharmaceutical company, today announces that following successful lab testing, the proprietary, skin-safe formulation of hypochlorous acid (HOCl) contained in the Company’s Spectricept™ product has efficacy in neutralising a wide range of pathogens, including Clostridium difficile spores (C. diff). C. diff spores are often found in health care facilities and hospitals, and the arising bacterium can infect the bowel, causing diarrhoea and other serious health effects. C.diff infections are challenging to treat and often recurrent.
LONDON--(BUSINESS WIRE)--SpectrumX, a UK-based healthcare and pharmaceutical company, today announces that it has signed a start-up agreement with an experienced leader with a strong background in conducting human challenge trials in infectious and respiratory diseases, to support the Company in the design and execution of a Phase I clinical trial for drug candidate SPX-001. The revolutionary therapy, based on SpectrumX’s licensed SPC-069 technology, is a hypochlorous acid (HOCl)-based nebulised treatment with broad-spectrum antipathogenic properties that has the potential to treat respiratory infections.
KNUTSFORD, England--(BUSINESS WIRE)--SpectrumX, a UK-based healthcare and pharmaceutical company, announced today that recent upgrades at its state-of-the-art production facility in Knutsford, Cheshire, will allow the Company to move forward for production of the pharmaceutical drug substance, SPC-069, for clinical trials.
LONDON--(BUSINESS WIRE)--SpectrumX, a UK-based healthcare and pharmaceutical company, today announces that it has appointed a head of microbiology, Annaliese Waite, BSc, and microbiologist Heather Lloyd, MSc, LIBMS (Licentiate of the Institute of Biomedical Science). These appointments form a new microbiology team at SpectrumX and further the Company’s strategy to expand its product R&D division.